Similarly, miR-122 was observed exhibiting better diagnostic performance in NASH and liver fibrosis in NAFLD patients than cytokeratin- (CK-) 18 and AST or ALT [7]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.